Exceptional non-trading items

RNS Number : 4657Q
Advanced Medical Solutions Grp PLC
09 April 2009



For Immediate Release

9 April 2009

Advanced Medical Solutions Group PLC 

(“AMS” or the “Company”)

Exceptional non-trading item

The Board of AMS has been pursuing a growth strategy which involves both organic opportunities and targeted acquisitions. As announced at the time of the preliminary results in March 2009, the Company’s organic growth and balance sheet was strong and the Board continues to pursue a number of exciting growth opportunities in both its Advanced Woundcare and Wound Closure and Sealants businesses.

With regards to acquisition opportunities, the Board has been pursuing an opportunity that had reached an advanced stage of discussions but which has now terminated. The costs relating to this aborted transaction are expected to be between £700,000 and £800,000which will be reported as an exceptional cost in the current financial year.

For further information, please contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

www.admedsol.com

Tel: +44 (0) 16 0654 5508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Richard Jones

Tim Pratelli

Daniel Adams

Tel: +44 (0) 20 7597 5970 

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 


This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCEALLNESNNEFE